Outsourcing Pharma

DECEMBER 13, 2021

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

Cardiology 145

Cardiology Dermatology Development Regulation 145

XTalks

OCTOBER 25, 2024

This collaboration aims to support patients with chronic and complex conditions, particularly in oncology, rheumatology and dermatology. million specialty care expansion in California, aimed at increasing access to cardiology, neurology and urology care, adding 44 physicians to meet rising patient needs.

Pharmacy 105

Pharmacy Dermatology Cardiology Drugs 105

FDA Law Blog

NOVEMBER 10, 2024

These have included clinical trials for rare diseases across metabolic (n=5), oncology (n=5), cardiology (n=3), dermatology (n=3), pulmonary (n=3), hematology (n=2), hepatology (n=2), ocular (n=2), transplant (n=1), gastrointestinal (n=1), immunology (n=1), infectious (n=1), neurology (n=1), orthopedic (n=1), and toxicology (n=1) indications.

Production 69

Production Clinical Development Development Regulation 69

Scienmag

DECEMBER 10, 2020

Jefferson researchers find that the genetic underpinnings of a skin disorder at birth indicate future heart problems PHILADELPHIA – Our skin tells us when we’ve spent too much time in the sun or when the dry air of winter has sucked away too much moisture. Now Jefferson researchers find that the skin can also foretell […].

Genetics 75

Genetics Research Dermatology Cardiology 75

The Pharma Data

MARCH 13, 2022

With a focus on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars.

Dermatology 52

Dermatology Cardiology Development Medicine 52

The Pharma Data

SEPTEMBER 15, 2020

The Inflammation & Immunology pipeline is focused on patients with autoimmune and chronic inflammatory diseases across rheumatology, gastroenterology and dermatology, with five distinct immuno-kinases, in oral and topical formulations, studied for potential treatment of 10 diseases, and three additional novel biologics in Phase 2 studies.

Vaccine 52

Vaccine Gene Therapy Vaccination Trials 52

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.

Sales 105

Sales Marketing Production Vaccine 105